En acceptant tous les cookies, vous êtes assuré de profiter au mieux de notre site internet, d'avoir, entre autres, accès à des contenus personnalisés et aux liens vers les réseaux sociaux. En n'acceptant que les cookies obligatoires, vous n'utiliserez qu'un minimum de cookies lors de votre navigation, mais certaines parties du site pourraient ne pas s'afficher correctement. Pour en savoir plus, consultez notre Politique de confidentialité.
15th EGA Regulatory and Scientific Affairs Conference had offered an update on recent regulatory developments, and answered the following answers:
- Looking to the future- EMA/HMA Strategy 2020 Work Plan- how will it impact the regulatory environment for pharmaceuticals?
- Tackling effects of the globalisation of pharmaceutical operations – challenges, opportunities and priorities
- Maintenance of medicinal products: is there a better way of handling it in practice?
- Borderline medicinal products - Do on-going changes to medical devices, food supplement legislations impact my products?
- How does the ICH 3QD guideline on elemental impurities affect my products?
- ISO IDMP is around the corner: are we set and ready to start with implementation?
Key Takeaways
- Regulatory implications of various changes in the legal and operational environment
- Electronic submission environment
Photos
Romuald Braun and Bernard Ferber at Amplexor's booth